09:48 AM EDT, 06/23/2025 (MT Newswires) -- Revolution Medicines ( RVMD ) said Monday the US Food and Drug Administration has granted Breakthrough Therapy Designation to its drug candidate daraxonrasib.

The designation is based on data from a phase 1 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, the clinical oncology company said.

The FDA's Breakthrough Therapy Designation is intended to expedite the development and review of potential new medicines designed to treat serious conditions and address significant unmet medical needs, the company said.

Price: 39.89, Change: +0.23, Percent Change: +0.58